

Literaturverzeichnis zum Titelthema „Nuklearmedizin – highlighted“

von Dr. Isabel Rauscher, Professor Dr. Matthias Eiber, Privatdozent Dr. Thomas Horn und
Professor Dr. Wolfgang Weber
Bayerisches Ärzteblatt 11/2019, Seite 544 ff.

1. Eder M, Schafer M, Bauder-Wust U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. *Bioconjug Chem.* 2012;23:688-697.
2. Perera M, Papa N, Roberts M, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. *Eur Urol.* 2019.
3. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. *Eur J Nucl Med Mol Imaging.* 2014;41:11-20.
4. Rauscher I, Duwel C, Haller B, et al. Efficacy, Predictive Factors, and Prediction Nomograms for (68)Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. *Eur Urol.* 2018;73:656-661.
5. Eiber M, Weirich G, Holzapfel K, et al. Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. *Eur Urol.* 2016;70:829-836.
6. Rauscher I, Duwel C, Wirtz M, et al. Value of (111) In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. *BJU Int.* 2017;120:40-47.
7. Maurer T, Weirich G, Schottelius M, et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. *Eur Urol.* 2015;68:530-534.
8. Maurer T, Schwamborn K, Schottelius M, et al. PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. *Clin Genitourin Cancer.* 2016;14:e549-e552.
9. Horn T, Kronke M, Rauscher I, et al. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. *Eur Urol.* 2019.
10. Maurer T, Robu S, Schottelius M, et al. (99m)Technetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. *Eur Urol.* 2019;75:659-666.

11. Rahbar K, Bode A, Weckesser M, et al. Radioligand Therapy With ¹⁷⁷Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer. *Clin Nucl Med*. 2016;41:522-528.
12. Heck MM, Retz M, D'Alessandria C, et al. Systemic Radioligand Therapy with (¹⁷⁷)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. *J Urol*. 2016;196:382-391.
13. Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with (¹⁷⁷)Lu-labelled PSMA-ligands ((¹⁷⁷)Lu-PSMA-RLT). *Eur J Nucl Med Mol Imaging*. 2019.
14. Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German Multicenter Study Investigating ¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. *J Nucl Med*. 2017;58:85-90.
15. Heck MM, Tauber R, Schwaiger S, et al. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with (¹⁷⁷)Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. *Eur Urol*. 2019;75:920-926.
16. Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with (²²⁵)Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. *J Nucl Med*. 2018;59:795-802.
17. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [¹⁷⁷ Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. *J Clin Oncol*. 2008;26:2124-2130.
18. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. *Endocr Relat Cancer*. 2010;17:R53-73.
19. Kwekkeboom DJ, de Herder WW, van Eijck CH, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. *Semin Nucl Med*. 2010;40:78-88.
20. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (¹⁷⁷)Lu-Dotatate for Midgut Neuroendocrine Tumors. *N Engl J Med*. 2017;376:125-135.
21. Bushnell DL, Jr., O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, et al. ⁹⁰Y-edotreotide for metastatic carcinoid refractory to octreotide. *J Clin Oncol*. 2010;28:1652-9.
22. Cwikla JB, Sankowski A, Seklecka N, Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. *Ann Oncol*. 2010;21:787-94.
23. Savelli G, Bertagna F, Franco F, Dognini L, Bosio G, Migliorati E, et al. Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of ⁹⁰Y-DOTA-D-Phe1-Tyr3 octreotide. *Cancer*. 2012;118:2915-24.

24. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. *Eur J Nucl Med Mol Imaging*. 2011;38:2125-35.
25. Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O, Sarnelli A, et al. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. *Neuroendocrinology*. 2013;97:347-54.
26. Paganelli G, Sansovini M, Ambrosetti A, Severi S, Monti M, Scarpi E, et al. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. *Eur J Nucl Med Mol Imaging*. 2014;41:1845-51.
27. Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. *Pancreas*. 2014;43:518-25.
28. Ianniello A, Sansovini M, Severi S, Nicolini S, Grana CM, Massri K, et al. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. *Eur J Nucl Med Mol Imaging*. 2016;43:1040-6.
29. Baum RP, Kluge AW, Kulkarni H, Schorr-Neufing U, Niepsch K, Bitterlich N, et al. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study. *Theranostics*. 2016;6:501-10.
30. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. *N Engl J Med*. 2017;376:125-35.